Key Highlights

  • OS Therapies (NYSE: OSTX) reached regulatory consensus with European agencies on an adaptive Phase 3 trial design for OST-HER2.
  • The trial targets resected pulmonary metastatic osteosarcoma.
  • Clinical startup is targeted for the fourth quarter of 2026, with a pre-BLA Type B FDA discussion scheduled for late 2026.
  • The program is supported by MHRA Leadership within Project Orbis, an accelerated global review pathway.

European Consensus on Trial Design

OS Therapies (NYSE: OSTX) has reached regulatory consensus with European agencies on an adaptive Phase 3 trial design evaluating OST-HER2 in patients with resected pulmonary metastatic osteosarcoma, a rare bone cancer with limited treatment options.

FDA Discussion and Project Orbis Support

The company is targeting clinical trial startup in the fourth quarter of 2026, alongside a pre-BLA Type B discussion with the FDA scheduled for late 2026. OS Therapies (NYSE: OSTX) said the program is supported by leadership from the UK's MHRA within Project Orbis, a framework designed to enable concurrent, accelerated review of oncology products across multiple regulatory agencies.

Targeting a Rare Disease Population

With regulatory alignment now secured in Europe, OS Therapies (NYSE: OSTX) is positioning OST-HER2 to move toward a global registration pathway for a patient population, resected pulmonary metastatic osteosarcoma, that currently lacks approved targeted therapies.

What is OST-HER2 being developed for?

Resected pulmonary metastatic osteosarcoma.

When is the Phase 3 trial expected to start?

Clinical startup is targeted for the fourth quarter of 2026.

What is Project Orbis?

A framework enabling concurrent, accelerated oncology review across multiple regulatory agencies, with MHRA leadership supporting this program.